Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,985 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Letter to the Editor regarding Response to "Letter to Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19".
Takazono T, Fujita S, Komeda T, Miyazawa S, Yoshida Y, Kitanishi Y, Kinoshita M, Kojima S, Shen H, Uehara T, Hosogaya N, Iwanaga N, Mukae H. Takazono T, et al. Among authors: yoshida y. Infect Dis Ther. 2024 Nov;13(11):2463-2467. doi: 10.1007/s40121-024-01054-6. Epub 2024 Sep 27. Infect Dis Ther. 2024. PMID: 39331323 Free PMC article. No abstract available.
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG. Ison MG, et al. Among authors: yoshida y. Lancet Infect Dis. 2020 Oct;20(10):1204-1214. doi: 10.1016/S1473-3099(20)30004-9. Epub 2020 Jun 8. Lancet Infect Dis. 2020. PMID: 32526195 Clinical Trial.
Evaluation of the Effect of Patient Education and Strengthening Exercise Therapy Using a Mobile Messaging App on Work Productivity in Japanese Patients With Chronic Low Back Pain: Open-Label, Randomized, Parallel-Group Trial.
Itoh N, Mishima H, Yoshida Y, Yoshida M, Oka H, Matsudaira K. Itoh N, et al. Among authors: yoshida y, yoshida m. JMIR Mhealth Uhealth. 2022 May 16;10(5):e35867. doi: 10.2196/35867. JMIR Mhealth Uhealth. 2022. PMID: 35576560 Free PMC article. Clinical Trial.
The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.
Kitano M, Matsuzaki T, Oka R, Baba K, Noda T, Yoshida Y, Sato K, Kiyota K, Mizutare T, Yoshida R, Sato A, Kamimori H, Shishido T, Naito A. Kitano M, et al. Among authors: yoshida y, yoshida r. Influenza Other Respir Viruses. 2020 Nov;14(6):710-719. doi: 10.1111/irv.12760. Epub 2020 Jun 13. Influenza Other Respir Viruses. 2020. PMID: 32533654 Free PMC article.
Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
Ando Y, Noshi T, Sato K, Ishibashi T, Yoshida Y, Hasegawa T, Onishi M, Kitano M, Oka R, Kawai M, Yoshida R, Sato A, Shishido T, Naito A. Ando Y, et al. Among authors: yoshida y, yoshida r. J Antimicrob Chemother. 2021 Jan 1;76(1):189-198. doi: 10.1093/jac/dkaa393. J Antimicrob Chemother. 2021. PMID: 33035324 Free PMC article.
6,985 results